Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma.

Literature DB >> 32598977

Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma.

Paul Windisch¹, Manuel Röhrich², Sebastian Regnery¹, Eric Tonndorf-Martini¹, Thomas Held¹, Kristin Lang¹, Denise Bernhardt¹, Stefan Rieken¹, Frederik Giesel², Uwe Haberkorn³, Jürgen Debus⁴, Sebastian Adeberg⁵.

Abstract

Fibroblast Activation Protein (FAP)-specific Positron Emission Tomography (PET) has shown promising results in various cancers. This pilot study compares FAP-specific PET to MRI for treatment planning in 13 Glioblastoma patients. The resulting incongruent volumes could provide additional information for radiotherapy or biopsy planning.

Entities: Disease Gene Species

Keywords: Brain neoplasms; Fibroblasts; Glioblastoma; Positron emission tomography computed tomography; Radiotherapy

Mesh：

Substances：
Radiopharmaceuticals

Year: 2020 PMID： 32598977 DOI： 10.1016/j.radonc.2020.06.040

Source DB: PubMed Journal: Radiother Oncol ISSN： 0167-8140 Impact factor: 6.280

Keyword Cloud
Cited

17 in total

1. Clinical utility of [⁶⁸Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.

Authors: Liang Zhao; Yizhen Pang; Hua Zheng; Chengkun Han; Jianwei Gu; Long Sun; Hua Wu; Sangang Wu; Qin Lin; Haojun Chen
Journal: Eur J Nucl Med Mol Imaging Date: 2021-04-01 Impact factor: 9.236

Review 2. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors: Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal: Eur J Nucl Med Mol Imaging Date: 2022-01-31 Impact factor: 10.057

3. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.

Authors: Martina Sollini; Margarita Kirienko; Fabrizia Gelardi; Francesco Fiz; Noemi Gozzi; Arturo Chiti
Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-25 Impact factor: 9.236

Review 4. Transpathology: molecular imaging-based pathology.

Authors: Mei Tian; Xuexin He; Chentao Jin; Xiao He; Shuang Wu; Rui Zhou; Xiaohui Zhang; Kai Zhang; Weizhong Gu; Jing Wang; Hong Zhang
Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-13 Impact factor: 9.236

Review 5. Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.

Authors: Francesco Ceci; Andrei Iagaru; R Laudicella; N Quartuccio; G Argiroffi; P Alongi; L Baratto; E Califaretti; V Frantellizzi; G De Vincentis; A Del Sole; L Evangelista; S Baldari; S Bisdas
Journal: Eur J Nucl Med Mol Imaging Date: 2021-04-13 Impact factor: 10.057

Review 6. Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Authors: Paul Windisch; Daniel R Zwahlen; Stefan A Koerber; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal: Cancers (Basel) Date: 2020-09-15 Impact factor: 6.639

Review 7. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

Authors: Paul Windisch; Daniel R Zwahlen; Frederik L Giesel; Eberhard Scholz; Patrick Lugenbiel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal: EJNMMI Res Date: 2021-02-19 Impact factor: 3.138

Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma.

1. Clinical utility of [⁶⁸Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.

Review 2. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

3. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.

Review 4. Transpathology: molecular imaging-based pathology.

Review 5. Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.

Review 6. Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Review 7. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

8. A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer.

9. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.

Review 10. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma.

1. Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.

Review 2. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

3. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.

Review 4. Transpathology: molecular imaging-based pathology.

Review 5. Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.

Review 6. Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Review 7. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

8. A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer.

9. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.

Review 10. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

1. Clinical utility of [⁶⁸Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.